Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 25mg - suspension for injection - 25 mg/2ml - active: risperidone 25mg excipient: polyglactin carmellose sodium citric acid dibasic sodium phosphate dihydrate polysorbate 20 sodium chloride sodium hydroxide water for injection - risperdal consta is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent. risperdal consta also alleviates affective symptoms (such as depression, guilt-feelings, anxiety) associated with schizophrenia. in addition, risperdal consta also appears effective in maintaining the clinical improvement during continuation therapy in patients who have should an initial response to treatment with this agent.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 37.5mg - suspension for injection - 37.5 mg/2ml - active: risperidone 37.5mg excipient: polyglactin carmellose sodium citric acid dibasic sodium phosphate dihydrate polysorbate 20 sodium chloride sodium hydroxide water for injection - risperdal consta is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent. risperdal consta also alleviates affective symptoms (such as depression, guilt-feelings, anxiety) associated with schizophrenia. in addition, risperdal consta also appears effective in maintaining the clinical improvement during continuation therapy in patients who have should an initial response to treatment with this agent.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 50mg - suspension for injection - 50 mg/2ml - active: risperidone 50mg excipient: polyglactin carmellose sodium citric acid dibasic sodium phosphate dihydrate polysorbate 20 sodium chloride sodium hydroxide water for injection - risperdal consta is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent. risperdal consta also alleviates affective symptoms (such as depression, guilt-feelings, anxiety) associated with schizophrenia. in addition, risperdal consta also appears effective in maintaining the clinical improvement during continuation therapy in patients who have should an initial response to treatment with this agent.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 0.5mg - orodispersible tablet - 0.5 mg - active: risperidone 0.5mg excipient: aspartame carbomer gelatin glycine iron oxide red mannitol peppermint oil polacrilin simeticone sodium hydroxide - risperdal is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 1mg - orodispersible tablet - 1 mg - active: risperidone 1mg excipient: aspartame carbomer gelatin glycine iron oxide red mannitol peppermint oil polacrilin simeticone sodium hydroxide - risperdal is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 2mg; risperidone 2mg - orodispersible tablet - 2 mg - active: risperidone 2mg excipient: aspartame carbomer 934p gelatin glycine iron oxide red mannitol peppermint oil polacrilin simeticone sodium hydroxide active: risperidone 2mg excipient: aspartame carbomer 934p gelatin glycine iron oxide red mannitol peppermint oil polacrilin simeticone sodium hydroxide xanthan gum - risperdal is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 3mg - orodispersible tablet - 3 mg - active: risperidone 3mg excipient: aspartame carbomer 934p gelatin glycine iron oxide red mannitol peppermint oil polacrilin simeticone sodium hydroxide xanthan gum - risperdal is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 4mg - orodispersible tablet - 4 mg - active: risperidone 4mg excipient: aspartame carbomer 934p gelatin glycine iron oxide red mannitol peppermint oil polacrilin simeticone sodium hydroxide xanthan gum - risperdal is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - canagliflozin hemihydrate 102mg equivalent to canagliflozin 100 mg - film coated tablet - 100 mg - active: canagliflozin hemihydrate 102mg equivalent to canagliflozin 100 mg excipient: croscarmellose sodium hyprolose lactose magnesium stearate microcrystalline cellulose opadry ii yellow 85f92209 - invokana is indicated in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise, to improve glycaemic control as: monotherapy: when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. add-on combination therapy: combination therapy with other anti-hyperglycaemic agents including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - canagliflozin hemihydrate 306mg equivalent to canagliflozin 300 mg - film coated tablet - 300 mg - active: canagliflozin hemihydrate 306mg equivalent to canagliflozin 300 mg excipient: croscarmellose sodium hyprolose lactose magnesium stearate microcrystalline cellulose opadry white 85f18422 - invokana is indicated in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise, to improve glycaemic control as: monotherapy: when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. add-on combination therapy: combination therapy with other anti-hyperglycaemic agents including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.